EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety of Live Attenuated MMR, Varicella, and Yellow Fever Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologic and Targeted Synthetic Therapy: A Propensity-Score-Matched Analysis

Niven Wang, Abdelrahman Yousef iD, Kevin Nguyen iD, Timothy Mok, Mahmoud Yousef iD, Ahmed Telbany, Abu Baker Sheikh iD, Christopher Chang, Swathi Paleti

Vaccines · 26.05.2026 · 14 (6) · 474

DOI: 10.3390/vaccines14060474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 26.05.2026. Verfasst von Niven Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, The University of New Mexico Health Sciences Center, University of New Mexico, Albuquerque, NM 87131, USA. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Live attenuated vaccines (LAVs) are generally avoided in patients with inflammatory bowel disease (IBD) receiving immunomodulatory therapy due to concerns about infection risk. However, real-world data evaluating their safety in this population remain limited. We aimed to assess adverse outcomes following LAV administration in IBD patients treated with biologic agents.

Methods

We conducted a retrospective cohort study using the TriNetX multi-institutional database. Adults with IBD receiving immunomodulatory therapy were categorized into two cohorts: those who received an LAV and those who did not. Biologic therapies included tumor necrosis factor inhibitors (infliximab, and adalimumab), integrin antagonists (vedolizumab), interleukin (IL)-12/23 inhibitors (ustekinumab), IL-23 inhibitors (risankizumab, and guselkumab), and Janus kinase inhibitors (tofacitinib, and upadacitinib). LAVs included measles–mumps–rubella (MMR), varicella (Varivax), and yellow fever vaccines. Propensity score matching was performed based on age, sex, IBD subtype (Crohn’s disease vs. ulcerative colitis), and biologic class. Patients with outcomes prior to the risk window were excluded. Adverse outcomes within six months included hospitalization, emergency department (ED) visits, fever, rash, and encephalitis.

Results

A total of 672 patients were included in each propensity-score-matched cohort. Live attenuated vaccine (LAV) administration was not associated with significantly increased adverse outcomes compared with no LAV exposure during the six-month follow-up period. Hospitalization occurred in 14.9% versus 15.3% of patients, respectively (risk ratio [RR] 0.97; 95% confidence interval [CI] 0.75–1.25; p = 0.819), while emergency department visits occurred in 12.6% vs 11.3% (RR 1.12; 95% CI 0.84–1.50; p = 0.450). There were no significant differences in fever (3.6% vs. 3.3%; RR 1.09; 95% CI 0.62–1.93; p = 0.764) or rash (4.0% vs. 2.7%; RR 1.50; 95% CI 0.83–2.70; p = 0.172). No cases of measles, mumps, rubella, varicella, yellow fever, or encephalitis were identified in either cohort during follow-up.

Conclusions

LAVs were not associated with an increased risk of adverse outcomes within one day to six months among IBD patients receiving immunomodulatory therapy. These real-world findings suggest comparable short-term outcomes between the cohorts of patients with IBD receiving biologic or targeted synthetic therapy who met the predefined eligibility criteria including age ≥ 18 years, and vaccination occurring between two weeks and six months after biologic initiation regarding LAV use in patients with IBD receiving biologic agents.

Schlagwörter

Stichwörter der Autor:innen

immunomodulatory therapyinflammatory bowel diseaseinfliximablive attenuated vaccinesvedolizumab

Autor:innen und Institutionen

  • Internal Medicine Department, The University of New Mexico Health Sciences Center, University of New Mexico, Albuquerque, NM 87131, USA.
  • The University of Texas Health Science Center at Houston, Houston, TX 77054, USA.
  • General Medicine Department, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
  • Division of Gastroenterology and Hepatology, The University of New Mexico Health Sciences Center, University of New Mexico, Albuquerque, NM 87131, USA.
  • Gastroenterology Department, Raymond G. Murphy Veterans Affairs Medical Center, Albuquerque, NM 87108, USA.

ORCID-Profile: Abdelrahman Yousef, Kevin Nguyen, Mahmoud Yousef, Abu Baker Sheikh

Zitieren

APA

Wang, N., Yousef, A., Nguyen, K., Mok, T., Yousef, M., Telbany, A., Sheikh, A. B., Chang, C., & Paleti, S. (2026). Safety of Live Attenuated MMR, Varicella, and Yellow Fever Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologic and Targeted Synthetic Therapy: A Propensity-Score-Matched Analysis. Vaccines, 14(6), 474. https://doi.org/10.3390/vaccines14060474

Vancouver

Wang N, Yousef A, Nguyen K, Mok T, Yousef M, Telbany A, et al. Safety of Live Attenuated MMR, Varicella, and Yellow Fever Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologic and Targeted Synthetic Therapy: A Propensity-Score-Matched Analysis. Vaccines. 2026;14(6):474. doi:10.3390/vaccines14060474

BibTeX
@article{Wang2026,
  author = {Wang, Niven and Yousef, Abdelrahman and Nguyen, Kevin and Mok, Timothy and Yousef, Mahmoud and Telbany, Ahmed and Sheikh, Abu Baker and Chang, Christopher and Paleti, Swathi},
  title = {Safety of Live Attenuated MMR, Varicella, and Yellow Fever Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologic and Targeted Synthetic Therapy: A Propensity-Score-Matched Analysis},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {6},
  pages = {474},
  doi = {10.3390/vaccines14060474}
}
Kostenlos starten →